TTR and amyloidosis: Acoramidis (formerly AG10) is an orally administered small-molecule drug specifically designed to mimic the protective T119M TTR variant—a naturally occurring mutation that enhances tetramer stability and reduces the risk of amyloidosis even in the presence of pathogenic variants.